Tumor infiltrating leukocytes (tils) during progressive tumor growth and BCG-mediated tumor regression.
Tumor regression was induced by intralesional injection with BCG, 7 days after inoculation of line 10 hepatocellular carcinoma cells into strain 2 guinea pigs. Tumor-infiltrating leukocytes (TILS) were characterized immunohistochemically with 11 monoclonal antibodies (MoAbs) during the induction phase of line 10-immunity, and during immune-mediated regression of the tumor, at days 12 and 28 after tumor cell inoculation, respectively. At day 5 after BCG-injection (day 12 after tumor cell inoculation), there were no major differences between the TIL subpopulations of the BCG-treated and untreated tumors. The TILS were mainly T-cells, as identified by MoAbs against Pan T-cells (CT5), T-cytotoxic/suppressor cells (CT6) and T-helper/inducer cells (H155). A limited number of macrophages was also present. However, at day 21 after BCG-treatment (28 days after tumor cell inoculation), the fibrous stroma was increased dramatically in most of the BCG-treated tumors, and as a result, the tumor cell islets were smaller than in control tumors. In the BCG treated tumors, the numbers of T-cells and macrophages were increased. In growing and regressing tumors, MHC class I and II antigens were strongly expressed in TILS and in the tumor stroma. Line 10 tumor cells prior to inoculation expressed no MHC class I or II antigens. In the centers of the tumor islets at days 12 and 28, expression of these antigens was not found. However, MHC class I and II antigens were expressed on tumor cells at sites where they lay close to the fibrous stroma or TILS. This observation was made in progressively growing tumors and was most apparent in BCG-treated tumors.
Steerenberg
P A
PA
Laboratory for Pathology, National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands.
De Jong
W H
WH
Elgersma
A
A
Burger
R
R
Poels
L G
LG
Claessen
A M
AM
Den Otter
W
W
Ruitenberg
E J
EJ
D000818:Animals; D000911:Antibodies, Monoclonal; D001500:BCG Vaccine / Q000627:therapeutic use; D005260:Female; D006168:Guinea Pigs; D006649:Histocompatibility Antigens / Q000032:analysis; D007150:Immunohistochemistry; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008297:Male; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000628:therapy; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D001500:BCG Vaccine; D006649:Histocompatibility Antigens